NMR RECEPTOR IMAGING

这项研究的目的是扩展我们以前的磁力 磁共振(MR)受体成像的研究和开发 免疫特异性造影剂在体内的表征 癌症。这些试剂理想地充当细胞的分子探针。 正常组织或肿瘤组织中的表面结构。 在之前的资助期内，我们成功地 合成和定向超顺磁性磁偶联物 肝细胞去唾液酸糖蛋白受体与胆囊收缩素的关系 胰腺细胞上的(CCK)受体，并显示出改善 良、恶性病变的鉴别(MR受体 成像)。在目前的项目中，我们建议a)完成 胰腺MR受体成像的研究及b) 将先前的研究扩展到存在的抗原和/或受体位置 在恶性细胞上。我们提供的数据是关于 基于单晶氧化铁的磁性免疫结合物 纳米化合物(Mion)包括优化我们的研究 偶联策略，并表明大多数抗体的亲和力 可以通过接合保留。拟议的研究 对成功的体内细胞培养实验和体内实验进行了阐述 利用这种抗体Mion偶联物进行磁共振成像 肿瘤细胞表面结构(Mion-L6)或内化 车厢(Mion-BR96)。我们期待着结果、模型 而这项研究的接合技术可以用于 评估多种肿瘤系统中的细胞表面结构 (乳腺癌、肺癌、盆腔恶性肿瘤、淋巴瘤等) 肿瘤抗原的磁共振成像有望实现活体分型 以加强对癌症的检测和预测 化学结合物和联合免疫治疗的疗效 免疫毒素。

The goal of this research is to extend our previous magnetic resonance (MR) receptor imaging research and develop novel immunospecific contrast agents for the in vivo characterization of cancer. These agents ideally act as ~molecular probes~ for cell surface structures either in normal tissue or in tumor tissue. During the previous funding period, we have successfully synthesized and directed superparamagnetic magnetoconjugates to asialoglycoprotein receptors on hepatocytes and to cholecystokinin (CCK) receptors on pancreas cells and demonstrated improved differentiation of benign and malignant lesions (MR receptor imaging). In the current Project we propose to a) complete the investigations of MR receptor imaging of the pancreas and b) to extend previous research to antigenic and/or receptor sites present on malignant cells. We present data on magnetoimmunoconjugates based on a monocrystalline iron oxide nanocompound (MION) including studies to optimized our coupling strategies and showed that most of the antibody affinity can be retained through conjugation. The proposed research expands on successful in vivo cell culture experiments and in vivo MR imaging with such antibody MION conjugates directed to tumor cell surface structures (MION-L6) or internalized compartments (MION-BR96). We anticipate that results, models and conjugation technology from this research can be used to assess cell surface structure in a variety of neoplastic systems (breast cancer, lung cancer, pelvic malignancies, lymphoma etc.) MR imaging of tumor antigens is expected to allow in vivo typing of malignant tissues, to enhance detection of cancer and to predict efficacy of immunotherapy with chemoconjugates and immunotoxins.